Endocrine side effects of immune checkpoint inhibitors

Endocrine side effects of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we...

Full description

Bibliographic Details
Main Authors:	Zulma Cardona, Jeffrey A. Sosman, Sunandana Chandra, Wenyu Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Endocrinology
Subjects:	immune checkpoint inhibitor (ICI) endocrine side effects hypophysitis thyroiditis type1 diabetes adrenalitis
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1157805/full

Similar Items

Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
by: Won Sang Yoo, et al.
Published: (2023-12-01)

Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study
by: E. V. Poddubskaya, et al.
Published: (2019-12-01)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
by: Stavroula A. Paschou, et al.
Published: (2022-03-01)

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
by: Hyemi Kwon, et al.
Published: (2022-12-01)

Endocrine side effects during cancer treatment. Lecture for practitioners
by: Anastasiya A. Glibka, et al.
Published: (2022-08-01)

Endocrine Side Effects in Patients Treated with Immune Checkpoint Inhibitors: A Narrative Review
by: Nicia I. Profili, et al.
Published: (2023-08-01)

Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients
by: Fouad Mitri, et al.
Published: (2024-03-01)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
by: Cristiane J. Gomes-Lima, et al.
Published: (2023-09-01)

Routine Screening for Central and Primary Adrenal Insufficiency during Immune-Checkpoint Inhibitor Therapy: An Endocrinology Perspective for Oncologists
by: Irena Druce, et al.
Published: (2022-07-01)

Immune-related endocrine disorders in novel immune checkpoint inhibition therapy
by: Le Min
Published: (2016-12-01)

Body mass index as a possible predictor of the development of endocrine immune-mediated adverse events during immune checkpoint inhibitors therapy
by: A. A. Glibka, et al.
Published: (2024-04-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Correction of endocrine complications of oncoimmunotherapy
by: E. A. Pigarova, et al.
Published: (2023-04-01)

Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario
by: Calogera Claudia Spagnolo, et al.
Published: (2022-12-01)

Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
by: Agnese Barnabei, et al.
Published: (2022-02-01)

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study
by: Lucia Parlati, et al.
Published: (2023-05-01)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
by: Jing Xiang, et al.
Published: (2023-12-01)

Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine
by: Elisa Longhitano, et al.
Published: (2023-03-01)

Endocrine Toxicities of Antineoplastic Therapy: The Adrenal Topic
by: Agnese Barnabei, et al.
Published: (2022-01-01)

Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review
by: Sara Menotti, et al.
Published: (2023-07-01)

Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy
by: Kaixiao Zhou, et al.
Published: (2022-12-01)

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
by: Piaohong Chen, et al.
Published: (2023-05-01)

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
by: Brigida Anna Maiorano, et al.
Published: (2021-09-01)

Editorial: Endocrine malignancies: from pathophysiology to current clinical and surgical therapeutic approaches
by: M. Tarallo, et al.
Published: (2023-06-01)

Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
by: Sabrina Chiloiro, et al.
Published: (2023-02-01)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
by: Majid Moshirfar, et al.
Published: (2022-09-01)

Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management
by: Krishna Moturi, et al.
Published: (2023-12-01)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
by: Jenny Hui Ling Chieng, et al.
Published: (2022-05-01)

Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors—A Single-Center Study
by: Anna Lea Amylidi, et al.
Published: (2023-12-01)

The autoimmune IgG4 -associated endocrine pathology
by: Marina Yu. Yukina, et al.
Published: (2017-11-01)

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
by: Mariana Ornelas, et al.
Published: (2023-07-01)

Functioning endocrine tumors in pregnancy: diagnostic and therapeutic challenges
by: Kripa E Cherian, et al.
Published: (2021-01-01)

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
by: Moran Gvili Perelman, et al.
Published: (2024-01-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model
by: Abdulmohammad Pezeshki, et al.
Published: (2024-03-01)

Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
by: Mona A. Marie, et al.
Published: (2022-12-01)

Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series
by: Antonella Laria, et al.
Published: (2021-08-01)

Incidence of Immune Checkpoint Inhibitor–Induced Myocarditis During the COVID‐19 Pandemic
by: Alexi Vasbinder, et al.
Published: (2024-03-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. Loosen, et al.
Published: (2021-03-01)

Impact of antibiotics on the efficacy of immune checkpoint inhibitors in the treatment of primary liver cancer
by: Jia-Ren Wang, et al.
Published: (2022-09-01)